Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial

Ahluwalia, MS; Rogers, LR; Chaudhary, R; Newton, H; Ozair, A; Khosla, AA; Nixon, AB; Adams, BJ; Seon, B; Peereboom, DM; Theuer, CP

Ahluwalia, MS (通讯作者)，Cleveland Clin, Rose & Ella Burkhardt Brain Tumor & Neurooncol Ct, Cleveland, OH 44195 USA.;Ahluwalia, MS (通讯作者)，Baptist Hlth South Florida, Miami Canc Inst, Miami, FL 33131 USA.;Ahluwalia, MS (通讯作者)，Florida Int Univ, Herbert Wertheim Coll Med, Miami, FL 33199 USA.

COMMUNICATIONS MEDICINE, 2023; 3 (1):

Abstract

BackgroundGlioblastoma (GBM), the most lethal primary brain tumor, has limited treatment options upon recurrence after chemoradiation and bevacizumab.......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索